GET DAILY SIGNALSCONMED (CNMD) Climbs +12.8% Amid Takeover Speculation and Strong Earnings
Key Takeaways
- CNMD climbed roughly 12.8% over the last 30 days, from about $47.33 on October 5, 2026 to approximately $53.38 in early November.
- The advance was amplified by renewed media reports that CONMED is weighing strategic alternatives, including a potential sale, following private-equity interest.
- Third-quarter 2026 results reported on October 28 showed adjusted EPS of $1.04 versus a $1.00 consensus and 6.7% organic constant-currency revenue growth.
- Management raised fiscal 2026 adjusted EPS guidance to $4.54–$4.61 and narrowed its full-year revenue outlook.
- Several analysts lifted price targets after the report, including JPMorgan (to $50) and Wells Fargo (to $49).
- The rally remains partly speculation-driven; the company has not confirmed any sale process and has declined to comment on rumors.
- Get more details on Price Targets, Earnings, and Forecast on additional pages.
- Explore Trending AI Robots for automated, data-driven trading strategies across thousands of tickers.
Understanding CONMED’s Business and Market Position
CONMED Corporation is a medical technology company that designs, manufactures, and sells surgical devices and equipment used by surgeons, hospitals, and ambulatory surgery centers. Founded in 1970 and headquartered in Largo, Florida, the company operates through two primary product families: Orthopedic Surgery and General Surgery.
Its portfolio is anchored by three growth platforms: AirSeal, an insufflation system for laparoscopic and robotic procedures; Buffalo Filter, a surgical smoke evacuation franchise; and BioBrace, a bioinductive implant for soft tissue repair. A large share of revenue comes from recurring, single-use consumables, which supports a comparatively predictable revenue stream. CONMED generated roughly $1.37 billion in revenue in fiscal 2025, with a substantial international presence across more than 100 countries. Investors follow the stock for its exposure to minimally invasive and robotic-assisted surgery trends, its smoke-evacuation legislative tailwinds, and its portfolio of procedure-driven consumables. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CNMD Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, CNMD rose about 12.8%, moving from a closing price near $47.33 on October 5, 2026 to approximately $53.38 in early November. Much of that gain arrived in a single sharp advance in early November, when shares jumped more than 13% from the prior session's close on renewed takeover speculation.
The trailing three-month picture is more tempered but equally volatile. Measured against early August levels around $50, the stock is up roughly 6% over the quarter. That relatively modest net change masks a choppy path: an early-August spike toward the low $50s, a September pullback into the mid-$40s, a steady October recovery following third-quarter earnings, and a fresh surge in early November. The overall trend reflects an improving fundamental backdrop layered on top of intermittent deal speculation.
What Drove CNMD Stock Price in the Last 30 Days
The sharpest driver was renewed reporting that CONMED is exploring strategic options, including a possible sale, after attracting interest from private-equity firms. Media reports in early November sent shares up more than 13% in a single session as investors priced in a potential acquisition premium. The company has not confirmed a sale process, and management has stated it does not comment on rumors.
The move was also supported by a solid earnings report. On October 28, 2026, CONMED reported third-quarter adjusted EPS of $1.04, ahead of the $1.00 consensus, alongside 6.7% organic constant-currency revenue growth driven by AirSeal and direct Buffalo Filter sales. Management raised full-year adjusted EPS guidance to $4.54–$4.61 and narrowed its 2026 revenue outlook, while issuing fourth-quarter revenue guidance of $364 million to $370 million. In response, analysts including JPMorgan and Wells Fargo raised their price targets, reinforcing the positive sentiment.
What Drove CNMD Stock Performance Over the Last Quarter
Over the trailing three months, the broader narrative shifted from concern to cautious optimism. Earlier in the period, shares consolidated and pulled back toward the mid-$40s in September, pressured by a voluntary Class II recall tied to a limited lot of suture anchors and broader questions about execution in domestic orthopedics.
The October earnings report marked a turning point. Organic growth reaccelerated, profitability beat expectations, and management's guidance increase signaled confidence in AirSeal, Buffalo Filter, and BioBrace. International strength, particularly in general surgery and orthopedics, helped offset softer domestic orthopedic sales. That improving operating story, combined with the earlier July report that CONMED was exploring a potential sale amid takeover interest, established the higher valuation base from which the early-November rally extended. Peers such as Stryker (SYK) and Medtronic (MDT) provide a reference point for how investors compare execution across surgical-device markets.
CNMD Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring CNMD should watch several factors in the months ahead. First, any confirmation, denial, or formal announcement regarding strategic alternatives or a potential sale will likely remain the dominant catalyst, given how much of the recent move is tied to speculation. Second, fourth-quarter and full-year results will test whether the organic growth momentum in AirSeal, Buffalo Filter, and BioBrace is durable, and whether domestic orthopedic sales stabilize. Third, the pace of state-level surgical smoke-evacuation legislation could expand Buffalo Filter's addressable market over time. Finally, macroeconomic considerations including tariffs, interest costs, and hospital capital budgets remain relevant, as management has flagged tariff and interest-expense headwinds. These factors, rather than short-term price swings, will help determine whether the recent gains are sustained. From what I see, this combination of catalysts and fundamentals is worth tracking closely.
Exploring Tickeron’s Trending AI Robots
In my research, I often review Tickeron’s Trending AI Robots to evaluate how different automated strategies are positioned across the market. The page highlights a curated selection of top-performing bots that trade thousands of tickers, offering a range of approaches in strategy, timeframe, and performance metrics rather than a single one-size-fits-all signal. This gives a practical way to consider data-driven complements to manual analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CNMD turns negative, indicating new downward trend
CNMD saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 72 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CNMD turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 38 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
CNMD broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CNMD entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 69 cases where CNMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
CNMD moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CNMD crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNMD advanced for three days, in 199 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. CNMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.358) is normal, around the industry mean (4.170). P/E Ratio (25.530) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.017) settles around the average of (0.010) among similar stocks. P/S Ratio (1.055) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical technology company, which provides surgical devices and equipment for minimally invasive procedures and monitoring
Industry MedicalNursingServices
Advertisement